Welcome to licensed pharmacies in Poland:
Non-prescription medicines delivery across Europe.
Frequently ordered: potency boosters (sildenafil OTC), quit smoking aids.
Is Wegovy good for weight loss? How effective is Wegovy?
Good morning
Is Wegovy good for weight loss? How effective is Wegovy?
* required field
* required field
Other messages will not be sent.
Suggested Products
Space for your product
Ewa Pilch Pharmacist, Editor
34 days ago
Further clinical trials are being carried out on the active substance Wegovy (semaglutide). The manufacturer of the drug regularly publishes the results of the research it receives at scientific conferences and congresses.
The use of the drug at a dose of 2.4 mg significantly reduces the risk of serious cardiovascular events in patients with obesity and concomitant cardiovascular diseases. The results of the study presented at the European Congress on Obesity (May 2025) show that already in the first 3 months, the risk of serious cardiovascular events (m.in. heart attack) was reduced by 37%, while in the first 6 months the risk of death from cardiac causes was reduced by 50%. The cardioprotective effect of Wegovy 2.4 mg has also been shown to be independent of weight loss.
A clinical trial of ESSENCE was also carried out, which showed a clinically relevant effect of Wegovy 2.4 mg in resolving fatty liver disease without increasing fibrosis in patients with MASH (fatty hepatitis associated with metabolic disorders). A reduction in the degree of liver fibrosis was also observed without aggravation of steatoinflammation. Currently, the process of marketing authorization of Wegovy is also proceeding as a priority in this indication.
At this year's Congress of the American Diabetes Association (ADA) (June 2025), the results of a clinical trial on the efficacy and safety of a higher dose of semaglutide - 7.2 mg were presented. The STEP UP clinical trial, which included obese and non-diabetic patients, showed that a higher dose of semaglutide resulted in a weight loss of at least 25% in approximately 33% of patients after 72 weeks of treatment. On the other hand, the average weight loss was about 21% after 72 weeks of using the preparation. The study also showed a high safety profile of the therapy. Side effects related to the digestive system were the most commonly reported. Usually, these were mild or moderate adverse reactions during the dose escalation phase. With the stabilization of the drug dose, the severity of adverse reactions decreased. In the case of the 7.2 mg dose, these adverse reactions resulted in discontinuation of therapy in approximately 3% of patients, compared to approximately 2% for the 2.4 mg dose.
In the European Union, the manufacturer of Wegovy (Novo Nordisk) plans to apply for a higher dose of Wegovy (7.2mg) for the second half of 2025.
Research is also being conducted to create a new, oral form of Wegovy.
Ewa Pilch Pharmacist, Editor
2 months ago
Wegovy is a semaglutide-containing drug for adults indicated for use in combination with a reduced-calorie diet and increased exercise for weight control, including weight reduction and maintenance. The use of the drug is recommended for people with a BMI of more than or equal to 30 kg/m2 (obesity) and exceeding or equal to 27 kg/m2 (overweight) with at least one concomitant condition associated with abnormal body weight, i.e. prediabetes, type 2 diabetes, hypertension, sleep apnea.
Clinical studies on the effectiveness of Wegovy have been conducted at a dose of 2.4 mg.
In 68-week clinical trials, consistent weight loss has been observed since initiation of treatment. More than 83% of the participants using Wegovy lost at least 5% of their body weight. It is worth noting that in over 47% of the subjects, the weight loss was at least 15% of the baseline value. The preparation allows to maintain clinically significant weight reduction at an average level of approx. 17% from the baseline value for 2 years. In people diagnosed with type 2 diabetes, a decrease in body weight was observed in more than 67% of the subjects by at least 5% of body weight, and in about 25% of the subjects by at least 15% of the initial body weight. People taking Wegovy also had a decrease in HbA1c (glycated haemoglobin) of around 17%, indicating an effect on the regulation of glycaemic levels by the medicine.
In addition to its effect on weight loss, Wegovy has a number of benefits for the patient. The SELECT clinical trial shows a 20% reduction in the incidence of major cardiovascular events compared to the placebo group (non-users). The SCORE study was also conducted, which showed a reduction in the relative risk of m.in heart attack and stroke by about 57% compared to people in the placebo group.
In patients with prediabetes, glycaemic control was observed.
The use of Wegovy has a beneficial effect on the patient's waist circumference, systolic blood pressure and physical function, which also reduces the risk of cardiovascular events. Changes in body composition have been observed by decreasing fat mass, including visceral fat.
The assumed goal of the Wegovy therapy is to reduce the patient's body weight and maintain it, and consequently to reduce the risk of developing complications of obesity, such as cardiovascular events (heart attack, stroke).
The drug can also be used in adolescents over 12 years of age, together with a calorie-reduced diet and increased physical exercise to control body weight in people with obesity and body weight over 60 kg. In adolescents, treatment should be discontinued and evaluated if there is no reduction in BMI of at least 5% after 12 weeks of treatment at 2.4 mg (or the maximum tolerated dose). The STEP TEENS study showed a weight reduction of at least 5% of body weight in more than 72% and at least 15% of baseline body weight in more than 53%.
In summary, Wegovy has a documented weight loss effect on the patient. The use of the drug has a beneficial effect, m.in others, on the cardiovascular system and physical fitness.
I have attached a link to check the availability of Wegovy and make a reservation at the pharmacy of your choice:
https://www.gdziepolek.pl/produkty/115667/wegovy-iniekcja/apteki
The price of the drug depends on the dose of the preparation. Some pharmacies provide prices of the preparation visible to logged-in users. I encourage you to contact selected pharmacies.
The preparation should be used in combination with a proper diet and physical exercise. The diet should be designed to provide all the necessary nutrients. It may be helpful to use the help of a qualified dietitian in developing a diet. If you are unable to consult in person, I encourage you to use the teleconsultation, e.g. via the Gdziepolek.pl portal:
https://www.gdziepolek.pl/telekonsultacja/z-dietetykiem
I encourage you to read additional materials that may be useful:
https://www.gdziepolek.pl/blog/nowe-leki-na-otylosc-i-cukrzyce-jak-nie-dac-sie-oszukac